QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach

Rangaraj, Nagarjun; Pailla, Sravanthi Reddy; Shah, Saurabh; Prajapati, Shubham; Sampathi, Sunitha

doi:10.1007/s13346-020-00803-7

Cited by 46 publications

(16 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cycloheximide was used for lymphatic flow blocking approach. It works by inhibiton of production of chylomicrons and inhibition of phagocytic activity of M cells thus block the pathway of lymphatic uptake of xenobiotics [1,30]. In addition, no interference of other absorption pathways and no death or other side effect was observed in cycloheximide treated rats during study.…”

Section: In Vivo Pharmacokinetic Study and Tissue Distribution Studiesmentioning

confidence: 95%

“…No sign of phase separation was observed in the ratio of lipid mixture that was selected throughout the study [29]. The surfactant and co-surfactant were selected based on solubility and HLB values which lead to required particle size, PDI, and stability [30].…”

Section: Screening Of Solid Lipid Liquid Lipid and Surfactantsmentioning

confidence: 99%

“…The surfactant's HLB values lies between 8 and 20 are able to form a stable formulation. Therefore, a surfactant blend of Tween 80 and Span 20 (2:1) were used to minimize the particle size and PDI and hence this blend was selected for development of NLCs [30].…”

Section: Screening Of Solid Lipid Liquid Lipid and Selection Of Surfa...mentioning

confidence: 99%

“…Despite the conventional surgical procedure for evaluation of lymphatic transport, we used the method from the published article [30]. In this method, no surgical procedure was carried out for the establishment of pharmacokinetic profile.…”

Section: In Vivo Pharmacokinetic Study and Tissue Distribution Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Quality by design (QbD)–based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies

Gurumukhi

Bari

2021

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

show abstract

Section: In Vivo Pharmacokinetic Study and Tissue Distribution Studiesmentioning

confidence: 95%

Section: Screening Of Solid Lipid Liquid Lipid and Surfactantsmentioning

confidence: 99%

Section: Screening Of Solid Lipid Liquid Lipid and Selection Of Surfa...mentioning

confidence: 99%

Section: In Vivo Pharmacokinetic Study and Tissue Distribution Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Quality by design (QbD)–based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies

Gurumukhi

Bari

2021

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

show abstract

“…The most common approaches for the evaluation of intestinal lymphatic transport are in vivo studies; for example, the chylomicron flow blocking approach is widely used [39,40]. On the contrary, in vitro methods are not still reported, even if this type of experiment can provide important information.…”

Section: In Vitro Chylomicron-like Structure Formationmentioning

confidence: 99%

Transmucosal Solid Lipid Nanoparticles to Improve Genistein Absorption via Intestinal Lymphatic Transport

et al. 2021

View full text Add to dashboard Cite

Genistein (GEN) is a soy-derived isoflavone that exhibits several biological effects, such as neuroprotective activity and the prevention of several types of cancer and cardiovascular disease. However, due to its poor water solubility and the extensive first-pass metabolism, the oral bioavailability of GEN is limited. In this work, solid lipid nanoparticles (SLN) were developed to preferentially reach the intestinal lymphatic vessels, avoiding the first-pass metabolism of GEN. GEN-loaded SLN were obtained by a hot homogenization process, and the formulation parameters were chosen based on already formulated studies. The nanoparticles were characterized, and the preliminary in vitro chylomicron formation was evaluated. The cell uptake of selected nanocarriers was studied on the Caco-2 cell line and intestinal mucosa. The SLN, characterized by a spherical shape, showed an average diameter (about 280 nm) suitable for an intestinal lymphatic uptake, good stability during the testing time, and high drug loading capacity. Furthermore, the intestinal mucosa and Caco-2 cells were found to uptake SLN. The approximately two-fold increase in particle size suggested a possible interaction between SLN and the lipid components of chylomicrons like phospholipid; therefore, the results may support the potential for these SLN to improve oral GEN bioavailability via intestinal lymphatic absorption.

show abstract

QbD-Steered Systematic Development of Drug Delivery Nanoconstructs: Vital Precepts, Retrospect and Prospects

Singh

Sharma

Kaur

et al. 2022

Biomedical Translational Research

View full text Add to dashboard Cite

QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach

Cited by 46 publications

References 56 publications

Quality by design (QbD)–based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies

Quality by design (QbD)–based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies

Transmucosal Solid Lipid Nanoparticles to Improve Genistein Absorption via Intestinal Lymphatic Transport

QbD-Steered Systematic Development of Drug Delivery Nanoconstructs: Vital Precepts, Retrospect and Prospects

Contact Info

Product

Resources

About